JP2024537137A5 - - Google Patents

Info

Publication number
JP2024537137A5
JP2024537137A5 JP2024520703A JP2024520703A JP2024537137A5 JP 2024537137 A5 JP2024537137 A5 JP 2024537137A5 JP 2024520703 A JP2024520703 A JP 2024520703A JP 2024520703 A JP2024520703 A JP 2024520703A JP 2024537137 A5 JP2024537137 A5 JP 2024537137A5
Authority
JP
Japan
Prior art keywords
kras
inhibitor
cancer
salt
sarcoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537137A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/045625 external-priority patent/WO2023059600A1/en
Publication of JP2024537137A publication Critical patent/JP2024537137A/ja
Publication of JP2024537137A5 publication Critical patent/JP2024537137A5/ja
Pending legal-status Critical Current

Links

JP2024520703A 2021-10-05 2022-10-04 Kras g12d阻害剤とイリノテカンとの組み合わせ及び関連する治療方法 Pending JP2024537137A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252405P 2021-10-05 2021-10-05
US63/252,405 2021-10-05
PCT/US2022/045625 WO2023059600A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with irinotecan and related methods of treatment

Publications (2)

Publication Number Publication Date
JP2024537137A JP2024537137A (ja) 2024-10-10
JP2024537137A5 true JP2024537137A5 (cg-RX-API-DMAC7.html) 2025-09-30

Family

ID=85803676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520703A Pending JP2024537137A (ja) 2021-10-05 2022-10-04 Kras g12d阻害剤とイリノテカンとの組み合わせ及び関連する治療方法

Country Status (10)

Country Link
US (1) US20250249003A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412720A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537137A (cg-RX-API-DMAC7.html)
KR (1) KR20240073115A (cg-RX-API-DMAC7.html)
CN (1) CN118354794A (cg-RX-API-DMAC7.html)
AU (1) AU2022361219A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233571A1 (cg-RX-API-DMAC7.html)
IL (1) IL311863A (cg-RX-API-DMAC7.html)
MX (1) MX2024004214A (cg-RX-API-DMAC7.html)
WO (1) WO2023059600A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2017172678A1 (en) 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation

Similar Documents

Publication Publication Date Title
JP2024537140A5 (cg-RX-API-DMAC7.html)
JP2024537139A5 (cg-RX-API-DMAC7.html)
JP2024537136A5 (cg-RX-API-DMAC7.html)
JP2022548791A5 (cg-RX-API-DMAC7.html)
JP2025000632A5 (cg-RX-API-DMAC7.html)
JP2025000629A5 (cg-RX-API-DMAC7.html)
JP2025000630A5 (cg-RX-API-DMAC7.html)
FI3849537T3 (fi) Yhdistelmäterapioita
JP2024540839A5 (cg-RX-API-DMAC7.html)
CN105311030B (zh) 用于抗肿瘤的螺取代化合物
CA2758300C (en) Checkpoint kinase 1 inhibitors for potentiating dna damaging agents
JP2024521788A5 (cg-RX-API-DMAC7.html)
IL311834A (en) Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods
IL311863A (en) Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods
ES2818110T3 (es) Tratamiento del cáncer con una combinación que comprende dinaciclib
JP2025512999A5 (cg-RX-API-DMAC7.html)
JP2023540809A5 (cg-RX-API-DMAC7.html)
JP2019516718A5 (cg-RX-API-DMAC7.html)
JP2002532392A5 (cg-RX-API-DMAC7.html)
JP2022535577A5 (cg-RX-API-DMAC7.html)
JP2012067116A5 (cg-RX-API-DMAC7.html)
CN101669941B (zh) 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物
JP2022530866A5 (cg-RX-API-DMAC7.html)
TW200813025A (en) Remedy for inflammatory bowel diseases
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合